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ABSTRACT
Objective: The link between CNS penetration of antiretrovirals and AIDS-defining neurologic
disorders remains largely unknown.
Methods: HIV-infected, antiretroviral therapy–naive individuals in the HIV-CAUSAL Collaboration
who started an antiretroviral regimen were classified according to the CNS Penetration Effec-
tiveness (CPE) score of their initial regimen into low (,8), medium (8–9), or high (.9) CPE score.
We estimated “intention-to-treat” hazard ratios of 4 neuroAIDS conditions for baseline regimens
with high and medium CPE scores compared with regimens with a low score. We used inverse
probability weighting to adjust for potential bias due to infrequent follow-up.
Results: A total of 61,938 individuals were followed for a median (interquartile range) of 37
(18, 70) months. During follow-up, there were 235 cases of HIV dementia, 169 cases of toxo-
plasmosis, 128 cases of cryptococcal meningitis, and 141 cases of progressive multifocal leuko-
encephalopathy. The hazard ratio (95% confidence interval) for initiating a combined
antiretroviral therapy regimen with a high vs low CPE score was 1.74 (1.15, 2.65) for HIV demen-
tia, 0.90 (0.50, 1.62) for toxoplasmosis, 1.13 (0.61, 2.11) for cryptococcal meningitis, and 1.32
(0.71, 2.47) for progressive multifocal leukoencephalopathy. The respective hazard ratios (95%
confidence intervals) for a medium vs low CPE score were 1.01 (0.73, 1.39), 0.80 (0.56, 1.15),
1.08 (0.73, 1.62), and 1.08 (0.73, 1.58).
Conclusions:We estimated that initiation of a combined antiretroviral therapy regimen with a high
CPE score increases the risk of HIV dementia, but not of other neuroAIDS conditions. Neurology®
2014;83:134–141
GLOSSARY
cART 5 combined antiretroviral therapy; CI 5 confidence interval; CPE 5 CNS Penetration Effectiveness; ICD-9 5 Inter-
national Classification of Diseases, ninth revision; NNRTI 5 nonnucleoside reverse transcriptase inhibitor.
AIDS-defining neurologic disorders, or neuroAIDS, include HIV dementia and the opportun-
istic infections toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoenceph-
alopathy.1–3 The incidence of neuroAIDS in developed countries decreased after the
introduction of combined antiretroviral therapy (cART) in 1996,2,4–9 but antiretroviral drug–
related neurotoxicity remains a concern.2,10–12
The risk of neuroAIDS may depend on the concentration of antiretrovirals in the CNS, which
is a function of their ability to penetrate the blood-brain barrier. Greater exposure of antiretrovirals
in the CNS may decrease the HIV RNA in the CSF,13 but may also be neurotoxic.14,15 One
proposed method to assess a drug’s penetrative ability into the CNS is via the CNS Penetration
Effectiveness (CPE) ranking system. In cohort studies to date, lower CPE ranks are associated with
higher CSF HIV RNA after adjusting for a number of clinical variables.13,16–18
While the association between CPE rank and CSF HIV RNA is reported, the connection
between CPE rank and clinical outcomes remains unclear.17,19–22 A randomized controlled trial
comparing a CNS-targeted therapy to a non-CNS–targeted therapy among 49 individuals with
HIV-associated neurocognitive disorders found no difference in improvement of neurocognitive
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performance after 16 weeks.23 An observa-
tional study in the United Kingdom found a
similar incidence of neuroAIDS in individuals
with high and low CPE scores.24
Herein, we present estimates of the effect of
CPE score on the incidence of 4 neuroAIDS
conditions among individuals withHIV-1 infec-
tion included in a large multinational collabora-
tion of cohort studies from Europe and the
United States.
METHODS Standard protocol approvals, registrations,
and patient consents. Research using the HIV-CAUSAL
Collaboration was determined to be nonhuman subjects research
by the Institutional Review Board of the Harvard School of
Public Health because it involves the study of existing data that
are analyzed in such a manner that the subjects cannot be
identified, as set forth in US federal regulations. Written
informed consent from patients was not required because all data
were completely anonymized.
Study population. The HIV-CAUSAL Collaboration includes
prospective cohort studies from 6 European countries and the
United States. All cohorts included in the HIV-CAUSAL
Collaboration were assembled prospectively and are based on
data collected for clinical purposes from national health care
systems that offer universal access to care. Each cohort in the
collaboration collected data prospectively, including all CD4
cell counts, HIV RNA measurements, treatment initiations,
deaths, and AIDS-defining illnesses (including the events of
interest: HIV dementia, toxoplasmosis, cryptococcal meningitis,
and progressive multifocal leukoencephalopathy).
The individual cohort studies used in these analyses are UK
CHIC (United Kingdom), ATHENA (the Netherlands), FHDH-
ANRSCO4 (France), SHCS (Switzerland), PISCIS (Spain), CoRIS/
CoRIS-MD (Spain), VACS-VC (US veterans), AMACS (Greece),
and AQUITAINE (France). Four cohorts of seroconverters with rel-
atively high CD4 counts did not have any neuroAIDS events and
were excluded from the analyses.
We restricted our analyses to individuals with HIV-1 infection
whomet the following criteria at baseline (starting in January 1998):
age 18 years or older, no history of AIDS (defined as the onset of any
category C AIDS-defining illness),25 antiretroviral therapy naive
(as defined elsewhere26), no pregnancy (when information was avail-
able), CD4 cell count and HIV RNA measured within the previous
6 months, and initiating a complete antiretroviral regimen (see
below) consisting only of drugs with known CPE ranks.
We conducted separate analyses for the following neuroAIDS
events: HIV dementia, toxoplasmosis, cryptococcal meningitis, or
progressive multifocal leukoencephalopathy. Non-Hodgkin lym-
phoma was not included as an event because we could not differen-
tiate primary brain lymphoma from other types of non-Hodgkin
lymphoma. We also looked at a combined endpoint of any of the
3 opportunistic infections (toxoplasmosis, cryptococcal meningitis,
or progressive multifocal leukoencephalopathy). The date of neuro-
AIDS was identified by the treating physicians. One of the contrib-
uting cohorts (VACS) used ICD-9 codes to identify incident
neuroAIDS cases. The other contributing cohorts used diagnostic
procedures that reflect standard clinical practice in Europe rather
than standardized research criteria.
For each patient, follow-up started on the date of initiation of
a complete antiretroviral regimen—defined as treatment with at
least 2 nucleoside reverse transcriptase inhibitors plus either one
or more protease inhibitors, one or more nonnucleoside reverse
transcriptase inhibitors (NNRTIs), one entry/fusion inhibitor, or
one integrase inhibitor—and ended at death, 12 months after the
most recent laboratory measurement, pregnancy (if known), the
cohort-specific administrative end of follow-up (ranging between
December 2003 and February 2013) or the event of interest,
whichever occurred earlier.
Assessment of antiretroviral CNS exposure. The 2010 CPE
ranking system is a proposed method for measuring the penetra-
tive ability of different antiretroviral drugs into the CNS. Each
drug is given a rank ranging from 1 to 4 based on pharmacoki-
netic and pharmacodynamic data, drug characteristics, results of
clinical studies, and effectiveness in reducing CSF viral load or
improving cognition. A rank of 4 represents the best penetration
or effectiveness.14,16 The CPE score for a given regimen is calculated
by summing the ranks of each drug in the regimen. We categorized
the CPE score for a regimen as low (,8), medium (8–9), or high
(.9) based on the distribution of the data (the cut points were
approximately at the median and the 75th percentile) (figure 1).
Because our estimates may be sensitive to the chosen cut points, we
also treated the CPE score as a continuous variable.
Statistical methods. Using a pooled logistic regression model,
we estimated the average “intention-to-treat” neuroAIDS hazard
ratio for a high and a medium baseline CPE score compared with a
low baseline CPE score. Under the assumption that the monthly
probability of an event is small (a condition satisfied in our study),
the parameters of our pooled logistic model closely approximate the
parameters of a Cox proportional hazards model.27 We computed
these estimates separately for each of the 4 neuroAIDS conditions as
well as for the combined endpoint of opportunistic infections. The
model included month of follow-up (restricted cubic splines with
4 knots at 1, 6, 24, and 60 months) and the following baseline
covariates: CD4 cell count (,200, 200–299, $300 cells/mL), HIV
RNA level (,10,000, 10,000–100,000, .100,000 copies/mL), sex,
acquisition group (heterosexual, homosexual/bisexual, injection drug
use, other or unknown), calendar year (1998, 1999–2000, 2001–
2003, $2004), age (,35, 35–50, .50 years), geographic origin
(North America or Western Europe, Sub-Saharan Africa, other, or
unknown), race (white, black, other, or unknown), years since HIV
diagnosis (,1, 1–4, $5 years or unknown), whether or not the
regimen was an NNRTI-based regimen, and cohort.
The variables we adjusted for in our models are associated
with CPE score and widely known to be associated with the out-
comes of interest. For example, a baseline CD4 cell count ,200
cells/mL, a baseline HIV RNA.100,000 copies/mL, and a base-
line age.50 years were associated with an increased odds of both
HIV dementia and the combined endpoint of opportunistic in-
fections compared with a baseline CD4 cell count$300 cells/mL,
a baseline HIV RNA ,10,000 copies/mL, and a baseline age
,35 years, respectively (data not shown).
To adjust for potential selection bias due to infrequent follow-
up, we computed inverse probability weights. Each patient in the
above logistic models received a time-varying weight inversely pro-
portional to the estimated probability of not being censored, for each
month that patient was followed.28,29 We fit a pooled logistic model
using the baseline covariates listed above, the baseline CPE score
category, and the most recent measurement of the following time-
varying covariates: CD4 cell count (restricted cubic spline with 5
knots at 10, 200, 350, 500, and 1,000 cells/mL), HIV RNA level
(,5,000, 5,000–10,000, 10,000–100,000,.100,000 copies/mL),
time since last laboratory measure (0, 1–2, 3–4, 5–6, $7 months),
and AIDS (any category C AIDS-defining illness other than the
neuroAIDS condition of interest), and estimated each patient’s
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probability of remaining uncensored in each month of follow-up.
The models for the weights were fit before the final models. The
weights were stabilized as described elsewhere28 and were then used
to fit the final weighted regression model. The estimated weights for
each of the 5 outcomes had mean 1.00 (first percentile: 0.96; 99th
percentile: 1.20).
We used robust variance estimators that take into account the
procedure of weight estimation to compute 95% confidence in-
tervals (CIs) for each of our estimates.30 Under the assumption
that the measured covariates are sufficient to adjust for confound-
ing and selection bias, our approach emulates a nonblinded ran-
domized trial in which patients were assigned to regimens with
1 of 3 CPE score categories.28
Several sensitivity analyses were performed for the outcome
HIV dementia: we (1) varied the CPE score of regimens that were
boosted with ritonavir because the CPE score category for
boosted ritonavir is somewhat ambiguous in 2 regimens; (2)
restricted the analysis to VACS in order to additionally adjust
for the VACS Index31; (3) excluded VACS from the analysis;
(4) estimated stabilized inverse probability weights to adjust for
potential selection bias due to death, a competing risk32; (5)
excluded cases of HIV dementia occurring in the first year; and
(6) restricted the analysis to individuals who initiated therapy
before the introduction of the first CPE scoring system in
2008. Exclusion of 0.15% of individuals with unusual treatment
combinations (e.g., boosted nelfinavir and unboosted darunavir)
did not materially affect the estimates. We also considered an
alternative categorization of the CPE score by dividing the lowest
category into 2 smaller categories (,6 and 6 to ,8), and esti-
mated the average log hazard ratios using a model that included a
flexible functional form for the continuous CPE score (restricted
cubic spline with 4 knots at 5, 7, 9, and 12). We fit a pooled
logistic model containing this form of the CPE score as well as the
previously listed baseline covariates, and adjusted for potential
selection bias due to infrequent follow-up as previously described.
All analyses were conducted with SAS 9.3 (SAS Institute, Cary,
NC). The LOGISTIC procedure was used to fit the weighted
regression models, and a nonparametric bootstrap with 500 sam-
ples was used to compute 95% CIs.
RESULTS A total of 61,938 individuals met the eli-
gibility criteria for our study; 38,786 (62%) initiated
a regimen with a low CPE score, 17,687 (29%) with a
medium CPE score, and 5,465 (9%) with a high CPE
score. The mean score for individuals on an NNRTI-
based regimen was 8.2 and the mean for individuals on
a non-NNRTI–based regimen was 7.3. Table 1 shows
the baseline characteristics of the study population by
CPE score category. Individuals with a high CPE score
were more likely to be female, heterosexual, initiating
therapy before 2004, and of Sub-Saharan African
origin. The median (interquartile range) follow-up
time was 37 (18, 70) months.
During follow-up, there were 235 cases of HIV
dementia, 169 cases of toxoplasmosis, 128 cases of
cryptococcal meningitis, and 141 cases of progressive
multifocal leukoencephalopathy. Forty individuals
developed 2 of the 4 neuroAIDS conditions, and
one individual developed 3. The incidence rate (per
10,000 person-years) was 9.0 for HIV dementia,
6.5 for toxoplasmosis, 4.9 for cryptococcal meningi-
tis, and 5.4 for progressive multifocal leukoencepha-
lopathy. The median (interquartile range) time from
cART initiation to the event of interest was 14 (2, 39)
months for HIV dementia, 4 (1, 16) months for
toxoplasmosis, 10 (1, 25) months for cryptococcal
Figure 1 Number initiating treatment by CPE score
Number of individuals initiating treatment by CNS Penetration Effectiveness (CPE) score (range 4–16), HIV-CAUSAL
Collaboration, 1998–2013.
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meningitis, and 3 (1, 14) months for progressive mul-
tifocal leukoencephalopathy.
Table 2 shows the 3 most frequently used cART
regimens with high, medium, and low CPE scores.
Compared with initiating a cART regimen with a low
CPE score, the hazard ratio (95% CI) for initiating a
cART regimen with a high CPE score was 1.74 (1.15,
2.65) for HIV dementia, 0.90 (0.50, 1.62) for toxo-
plasmosis, 1.13 (0.61, 2.11) for cryptococcal menin-
gitis, and 1.32 (0.71, 2.47) for progressive multifocal
Table 1 Baseline characteristics by CPE score category, HIV-CAUSAL Collaboration, 1998–2013
Baseline characteristics
Persons, % (n)
Low CPE score
(n 5 38,786)
Medium CPE score
(n 5 17,687)
High CPE score
(n 5 5,465)
CD4 cell count, cells/mL
<200 37.8 (14,674) 44.9 (7,939) 43.5 (2,377)
200 to <300 25.5 (9,890) 25.6 (4,521) 24.2 (1,320)
‡300 36.7 (14,222) 29.5 (5,227) 32.3 (1,768)
HIV RNA, copies/mL
<10,000 18.6 (7,215) 17.9 (3,172) 20.5 (1,121)
10,000–100,000 41.6 (16,136) 40.6 (7,176) 41.9 (2,292)
>100,000 39.8 (15,435) 41.5 (7,339) 37.6 (2,052)
Sex
Male 80.0 (31,016) 74.4 (13,157) 66.2 (3,618)
Female 20.0 (7,770) 25.6 (4,530) 33.8 (1,847)
Race
White 23.9 (9,285) 23.3 (4,125) 17.8 (970)
Black 13.9 (5,373) 20.0 (3,541) 21.9 (1,198)
Other 62.2 (24,128) 56.7 (10,021) 60.3 (3,297)
Age, y
<35 34.6 (13,418) 35.5 (6,280) 41.9 (2,289)
35–50 47.4 (18,382) 47.1 (8,327) 43.6 (2,384)
>50 18.0 (6,986) 17.4 (3,080) 14.5 (792)
Origin
North America or Western Europe 60.3 (23,373) 54.7 (9,671) 53.1 (2,903)
Sub-Saharan Africa 13.7 (5,321) 19.9 (3,516) 23.4 (1,277)
Other 9.3 (3,600) 7.5 (1,326) 6.6 (359)
Unknown 16.7 (6,492) 17.9 (3,147) 16.9 (926)
Acquisition group
Heterosexual 33.1 (12,853) 40.3 (7,129) 45.5 (2,488)
Homosexual/bisexual 41.8 (16,214) 32.2 (5,706) 28.4 (1,554)
Injection drug user 5.9 (2,264) 6.9 (1,213) 7.7 (418)
Other/unknown 19.2 (7,455) 20.6 (3,639) 18.4 (1,005)
Calendar year
1998 7.4 (2,865) 7.2 (1,283) 6.0 (326)
1999–2000 8.5 (3,291) 14.6 (2,578) 29.1 (1,593)
2001–2003 8.7 (3,362) 24.8 (4,381) 41.3 (2,257)
‡2004 75.4 (29,268) 53.4 (9,445) 23.6 (1,289)
Regimen
NNRTI-based 47.2 (18,295) 59.4 (10,501) 74.6 (4,079)
non-NNRTI–based 52.8 (20,491) 40.6 (7,186) 25.4 (1,386)
Abbreviations: CPE 5 CNS Penetration Effectiveness; NNRTI 5 nonnucleoside reverse transcriptase inhibitor.
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leukoencephalopathy (table 3). Compared with a low
CPE score, the respective hazard ratios (95% CIs) for
a medium CPE score were 1.01 (0.73, 1.39), 0.80
(0.56, 1.15), 1.08 (0.73, 1.62), and 1.08 (0.73,
1.58). Figure 2 shows the log hazard ratio against
the continuous CPE score for the combined end-
point of opportunistic infections and for HIV
dementia (see figure e-1 on the Neurology® Web site
at Neurology.org for the individual opportunistic
infections).
The hazard ratio of HIV dementia for a high
CPE score vs a low CPE score did not vary substan-
tially by CD4 cell count, age, sex, and type of cART
regimen (NNRTI-based vs non-NNRTI–based),
but the 95% CIs were wide (data not shown). The
hazard ratios and 95% CIs did not change with dif-
ferent specifications of the functional form for
month of follow-up (data not shown). None of the
sensitivity analyses described in the previous section
yielded appreciably different results (table e-1).
Varying the cut points of the CPE score did not
materially change the point estimates but resulted
in wider CIs. Excluding cases of HIV dementia
occurring in the first year of follow-up (table e-2)
did not materially change the estimates of the effect
of CPE score on HIV dementia.
Table 2 Most frequently used cART regimens with a low, medium, and high CPE
score, HIV-CAUSAL Collaboration, 1998–2013
Regimen No. of initiators CPE score (category)
Efavirenz, tenofovir, emtricitabine 14,839 7 (low)
Nelfinavir, zidovudine, lamivudine 3,368 7 (low)
Lopinavir, ritonavir, tenofovir, emtricitabine 3,342 7 (low)
Efavirenz, zidovudine, lamivudine 5,346 9 (medium)
Lopinavir, ritonavir, zidovudine, lamivudine 3,823 9 (medium)
Efavirenz, lamivudine, abacavir 1,837 8 (medium)
Nevirapine, zidovudine, lamivudine 3,373 10 (high)
Indinavir, ritonavir, zidovudine, lamivudine 757 10 (high)
Efavirenz, zidovudine, lamivudine, abacavir 409 12 (high)
Abbreviations: cART 5 combined antiretroviral therapy; CPE 5 CNS Penetration
Effectiveness.
Table 3 Hazard ratios for CPE score, HIV-CAUSAL Collaboration, 1998–2013
CPE score Person-years No. of events
Unadjusted
hazard ratio 95% CI
Adjusted
hazard ratioa 95% CI
HIV dementia
Low 140,962 127 1.00 Reference 1.00 Reference
Medium 86,799 72 0.97 0.72, 1.30 1.01 0.73, 1.39
High 32,097 36 1.55 1.06, 2.26 1.74 1.15, 2.65
Opportunistic infectionsb
Low 140,553 245 1.00 Reference 1.00 Reference
Medium 86,455 134 1.09 0.88, 1.34 0.99 0.80, 1.22
High 31,985 49 1.18 0.87, 1.62 1.08 0.77, 1.52
Toxoplasmosis
Low 140,983 106 1.00 Reference 1.00 Reference
Medium 86,807 45 0.86 0.60, 1.22 0.80 0.56, 1.15
High 32,099 18 0.94 0.57, 1.57 0.90 0.50, 1.62
Cryptococcal meningitis
Low 141,098 64 1.00 Reference 1.00 Reference
Medium 86,818 48 1.35 0.92, 1.98 1.08 0.73, 1.62
High 32,121 16 1.43 0.83, 2.48 1.13 0.61, 2.11
Progressive multifocal
leukoencephalopathy
Low 141,109 81 1.00 Reference 1.00 Reference
Medium 86,849 43 1.12 0.77, 1.64 1.08 0.73, 1.58
High 32,116 17 1.36 0.80, 2.33 1.32 0.71, 2.47
Abbreviations: CI 5 confidence interval; CPE 5 CNS Penetration Effectiveness.
aAdjusted for cohort, month of follow-up, baseline CD4 cell count, baseline HIV RNA level, sex, acquisition group, calendar
year, age, geographic origin, race, years since HIV infection, and type of drug regimen, as well as time-varying CD4 cell
count, RNA level, time since last measurement, and AIDS. Stabilized inverse probability weights were used to account for
censoring due to infrequent follow-up.
b Includes toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy.
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DISCUSSION We estimated that the incidence of
HIV dementia increases by more than 70% after ini-
tiating an antiretroviral regimen with a high CPE
score compared with a low score. However, we found
little change in the incidence of toxoplasmosis, cryp-
tococcal meningitis, and progressive multifocal leuko-
encephalopathy. These results are unexpected, and
the interpretation of our effect estimates needs to be
tempered by the limitations of our study.
In the only published study that has considered
CPE scores in relation to neuroAIDS among HIV-
positive individuals, the incidence of neuroAIDS
was similar for a baseline CPE score of 10 or greater
and for a baseline CPE score of 4 or less, but the
small number of events resulted in a wide 95% CI
(hazard ratio: 0.95; 95% CI: 0.53, 1.72). Further-
more, the study was not restricted to antiretroviral
therapy–naive individuals and effect estimates for
individual neuroAIDS conditions such as HIV
dementia were not provided.24 Other studies of the
association between CPE scores and risk of cognitive
impairment (but not neuroAIDS) have had conflict-
ing results.17,19–21,33
Our findings that CPE score does not affect the
incidence of opportunistic infections may not be par-
ticularly surprising, because the development of these
neuroAIDS conditions may be very closely connected
to the degree of impaired cell-mediated immunity
and not associated with antiretroviral penetration.4,5
In contrast, antiretroviral penetration into the brain
may lead to deposition of b-amyloid plaques, which
has been proposed as a possible explanation for a harm-
ful effect of high CPE score on HIV dementia.34 One
study observed a higher percentage of extracellular
b-amyloid in cART-treated patients than in untreated
HIV-positive individuals,35 and HIV-positive individ-
uals with HIV-associated dementia have higher levels
of intraneuronal b-amyloid immunoreactivity com-
pared with HIV-positive individuals without HIV-
associated dementia.34–36 However, the underlying
mechanism through which antiretroviral penetration
could cause HIV dementia remains unknown. The
hypothesis that antiretroviral penetration increases
the incidence of HIV dementia via deposition of
b-amyloid plaques requires further research to deter-
mine whether these associations are in fact causal.
Alternative pathways including antiretroviral-related
direct neuronal damage and mitochondrial toxicity
should also be evaluated.15
Another explanation for the higher dementia risk
for regimens with a high CPE score is that these regi-
mens are less effective to treat HIV disease, for exam-
ple, because of incomplete adherence: 68% of
individuals in the study deviated from their initial reg-
imen at some point. However, both the high average
proportion of follow-up spent on the initial regimen
(58%) and the lack of a strong association between
CPE score and opportunistic infections do not sup-
port this explanation.
Similar to any other observational study, the valid-
ity of our estimates relies on the untestable assump-
tion that the measured covariates were sufficient to
adjust for confounding and selection bias. It is possi-
ble that consideration of CPE scores is a factor for de-
cisions concerning antiretroviral regimens in patients
with neurocognitive symptoms. If individuals with
neurocognitive symptoms are more likely to initiate
antiretroviral regimens with higher CPE scores, the
estimated effect on dementia might be explained by
this confounding by indication. If this were the case,
we would expect the estimated effect on dementia to
disappear or to attenuate after a certain amount of
time. However, excluding cases of HIV dementia
occurring in the first year of follow-up does not mate-
rially change the results. Furthermore, restricting the
Figure 2 Estimated log hazard ratios and 95% confidence intervals
Estimated log hazard ratios and 95% confidence intervals for opportunistic infections (A)
(toxoplasmosis, cryptococcal meningitis, or progressive multifocal leukoencephalopathy)
and HIV dementia (B) comparing each CNS Penetration Effectiveness (CPE) score with a
CPE score of 4 (lowest), HIV-CAUSAL Collaboration, 1998–2013.
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analysis to individuals who initiated therapy before
the introduction of the first CPE scoring system in
2008 does not affect the results.
Some limitations of our study should be noted.
First, with relatively few events, the 95% CIs around
our effect estimates are wide. However, our study is
the largest one to date on this topic. Second, the cohorts
included in this analysis are from developed countries;
our results may not be generalizable to resource-limited
settings or to other health care systems. Third, with the
exception of VACS, the contributing cohorts used diag-
nostic procedures that reflect standard clinical practice
in Europe. Excluding VACS from the analysis, how-
ever, did not significantly alter the results. Fourth, while
our effect estimates are adjusted for cohort, we were not
able to adjust for the individual centers within each
cohort. Thus, some residual confounding due to cen-
ters within each cohort is theoretically possible. Finally,
the average duration of follow-up in our study was
approximately 3 years. Future studies will be needed
to investigate the effect of antiretroviral penetration
on the long-term incidence of neuroAIDS, as well as
the effect of newer antiretrovirals that are not well rep-
resented in current studies, including ours.
We estimated that initiation of a cART regimen
with a high CPE score increases the risk of HIV
dementia, but not of other neuroAIDS conditions.
These findings should be interpreted cautiously, and
additional studies are needed to examine the effect of
CPE score on the incidence of HIV dementia more
closely. Together with additional data on the safety
and effectiveness of different cART regimens, these re-
sults may be useful to plan the management of individ-
uals with HIV infection.
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